Hypothesis

Specific probiotic strains that produce high levels of GABA selectively activate vagal afferents via GABA‑B receptors on intestinal enterochromaffin cells, leading to increased brain‑stem locus coeruleus norepinephrine release. This noradrenergic surge suppresses microglial activation in the nucleus accumbens and prefrontal cortex, thereby alleviating depressive‑like behavior.

Mechanistic Rationale

• Gut microbes synthesize GABA that can act on epithelial GABA‑B receptors (see metabolitic pathways in [3]).
• Activation of these receptors triggers vagal afferent firing, a pathway shown necessary for probiotic mood effects ([2]).
• Vagal signaling boosts norepinephrine in the prefrontal cortex and nucleus accumbens, regions with documented neuroinflammatory signatures in MDD ([7]).
• Norepinephrine inhibits NF‑κB signaling in microglia, reducing pro‑inflammatory cytokines and reversing synaptic loss.

Testable Predictions

1. Oral administration of a high‑GABA Lactiplantibacillus plantarum strain will raise fecal GABA concentrations and urinary GABA metabolites more than a low‑GABA control strain ([4]).
2. Vagotomy will abolish the strain‑induced increase in prefrontal norepinephrine measured by microdialysis, while leaving luminal GABA levels unchanged.
3. Mice receiving the high‑GABA strain will show decreased Iba1‑positive microglial activation and lower IL‑1β levels in the nucleus accumbens and prefrontal cortex compared with controls.
4. Administering a GABA‑B receptor antagonist peripherally will block the behavioral antidepressant effect without affecting gut GABA production.

Experimental Design

• Subjects: Male and female C57BL/6J mice subjected to chronic unpredictable stress to induce depressive‑like phenotype.
• Groups: (i) vehicle, (ii) low‑GABA L. plantarum strain, (iii) high‑GABA L. plantarum strain, (iv) high‑GABA strain + vagotomy, (v) high‑GABA strain + peripheral GABA‑B antagonist (saclofen).
• Measurements: Fecal and urinary GABA (LC‑MS), vagal afferent electrophysiology, prefrontal norepinephrine (HPLC), microglial morphology (Iba1 immunostaining), cytokine panel (ELISA), sucrose preference and forced swim test.
• Analysis: Two‑way ANOVA with post‑hoc Tukey; mediation analysis to test whether norepinephrine changes mediate the link between vagal firing and microglial suppression.

Potential Confounds and Controls

• Strain differences in adhesion or colonization could affect GABA delivery; we will quantify luminal CFU counts to normalize dose.
• Stress‑induced alterations in gut permeability may influence metabolite absorption; we will measure serum FITC‑dextran to exclude leaky‑gut artifacts.
• Sex differences in vagal tone will be examined separately to ensure findings are not limited to one gender.

Significance

If confirmed, this hypothesis would shift the focus from broad‑spectrum probiotic use to precision selection of strains based on their GABA‑ergic vagal priming capacity. It provides a falsifiable, mechanism‑driven pathway that explains heterogeneity in clinical outcomes ([8],[9]) and offers biomarker‑guided strategies (vagal tone, urinary GABA) for personalized psychobiotic therapy in depression and related disorders.